Latest Breaking News On - லின் ஷென் - Page 1 : comparemela.com

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor News provided by Share this article Share this article BEIJING, Aug. 2, 2021 /PRNewswire/ Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China. JAB-21822 is Jacobio s innovative in-house small molecule anti-cancer drug, which is designed to target the KRAS G12C mutation. It will be used to treat advanced solid tumors with KRAS G12C mutation, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors. The global incidence of the KRAS G12C mutation in patients with NSCLC, ovarian cancer, CRC and pancreatic cancer reached approximately 295,000 in 2019. 

United statesLin shenYinxiang wangPrnewswire jacobio pharmaceuticalsProfessor lin shenBeijing cancerஒன்றுபட்டது மாநிலங்களில்லின் ஷென்ப்ரொஃபெஸர் லின் ஷென்பெய்ஜிங் புற்றுநோய்